Blog
RSS FeedPosted by Michael Wonder on 01 Mar 2023
Eptinezumab for the prevention of migraine
1 March 2023 - The recommendation was made after consideration of the evidence submitted by Lundbeck, a review of this submission ...
Posted by Michael Wonder on 28 Feb 2023
Baricitinib for the treatment of patients with severe alopecia areata
28 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Feb 2023
Axicabtagene ciloleucel for the treatment of adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more systemic therapies
28 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access ...
Posted by Michael Wonder on 27 Feb 2023
Doctor with Stage 4 cancer is refused access to lifesaving treatment on the NHS
27 February 2023 - Dr Asha Umrawsingh, 50, was first diagnosed with breast cancer in 2010. ...
Posted by Michael Wonder on 23 Feb 2023
Vir Biotechnology announces positive final draft guidance on sotrovimab from the UK’s NICE
22 February 2023 - Final draft guidance based on cost effectiveness evaluation of sotrovimab. ...
Posted by Michael Wonder on 23 Feb 2023
Daratumumab in combination with lenalidomide and dexamethasone for the first-line treatment of patients with multiple myeloma when stem cell transplantation is unsuitable
22 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 Feb 2023
Ataluren for the treatment of patients with Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
22 February 2023 - This guidance updates and replaces NICE highly specialised technologies guidance HST3 on the use of ataluren for ...
Posted by Michael Wonder on 22 Feb 2023
Ixazomib citrate and lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement ...
Posted by Michael Wonder on 21 Feb 2023
NICE recommends 3 treatments for COVID-19 in final draft guidance
21 February 2023 - Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and ...
Posted by Michael Wonder on 21 Feb 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of adults with PSMA positive hormone-relapsed metastatic prostate cancer after two or more therapies
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 21 Feb 2023
Rimegepant sulphate for the treatment or prevention of migraine
21 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of rimegepant ...
Posted by Michael Wonder on 17 Feb 2023
UK’s most expensive drug Libmeldy saved Teddi Shaw, but is too late for her sister
16 February 2023 - A toddler with a rare inherited condition has become the first child to be treated by ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
Posted by Michael Wonder on 17 Feb 2023
Mitapivat sulphate for the treatment of patients with pyruvate kinase deficiency
16 February 2023 - NICE is unable to make a recommendation on the the use of mitapivat sulphate (Pyrukynd) for the ...